Assessment of pulmonary 18 F-FDG-PET uptake and cytokine profiles in non-small cell lung cancer patients treated with radiotherapy and erlotinib

Siegel, 2016, Cancer statistics, CA Cancer J Clin, 66, 7, 10.3322/caac.21332 Traynor, 2004, Systemic treatment of advanced non-small cell lung cancer, Drugs Today (Barc), 40, 697, 10.1358/dot.2004.40.8.850472 Hernando, 2001, Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer, Int J Radiat Oncol Biol Phys, 51, 650, 10.1016/S0360-3016(01)01685-6 Rancati, 2003, Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study, Radiother Oncol, 67, 275, 10.1016/S0167-8140(03)00119-1 Bradley, 2005, Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non–small-cell lung carcinoma, Int J Radiat Oncol Biol Phys, 61, 318, 10.1016/j.ijrobp.2004.06.260 De Ruysscher, 2009, Increased 18F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): a prospective pilot study, Radiother Oncol, 91, 415, 10.1016/j.radonc.2009.01.004 Johnston, 2004, Inflammatory cell recruitment following thoracic irradiation, Exp Lung Res, 30, 369, 10.1080/01902140490438915 Roberts, 1993, Radiation pneumonitis: a possible lymphocyte-mediated hypersensitivity reaction, Ann Intern Med, 118, 696, 10.7326/0003-4819-118-9-199305010-00006 Ghafoori, 2008, Radiation-induced lung injury. Assessment, management, and prevention, Oncology (Williston Park), 22, 37 Roach, 1995, Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors, J Clin Oncol, 13, 2606, 10.1200/JCO.1995.13.10.2606 Taghian, 2001, Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel, J Natl Cancer Inst, 93, 1806, 10.1093/jnci/93.23.1806 Kimsey, 1994, Is radiation treatment volume a predictor for acute or late effect on pulmonary function? A prospective study of patients treated with breast-conserving surgery and postoperative irradiation, Cancer, 73, 2549, 10.1002/1097-0142(19940515)73:10<2549::AID-CNCR2820731016>3.0.CO;2-N Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to Gefitinib, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938 Hidalgo, 2001, Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies, J Clin Oncol, 19, 3267, 10.1200/JCO.2001.19.13.3267 Shepherd, 2005, Erlotinib in previously treated non–small-cell lung cancer, N Engl J Med, 353, 123, 10.1056/NEJMoa050753 Cappuzzo, 2010, Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study, Lancet Oncol, 11, 521, 10.1016/S1470-2045(10)70112-1 Bezjak, 2006, Symptom Improvement in lung cancer patients treated with erlotinib: quality of life analysis of the national cancer institute of canada clinical trials group study BR.21, J Clin Oncol, 24, 3831, 10.1200/JCO.2006.05.8073 Schneider, 2008, Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the trust study, J Thorac Oncol, 3, 1446, 10.1097/JTO.0b013e31818ddcaa Gurtner, 2011, Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression, Radiother Oncol, 99, 323, 10.1016/j.radonc.2011.05.035 Pérez-Soler, 2005, HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum, Oncologist, 10, 345, 10.1634/theoncologist.10-5-345 Hirsh, 2011, Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer, Curr Oncol, 18, 126, 10.3747/co.v18i3.877 Vahid, 2007, Erlotinib-associated acute pneumonitis: report of two cases, Can Respir J, 14, 167, 10.1155/2007/832605 Peerzada, 2010, Pulmonary toxicities of biologics: a review, Anticancer Drugs, 21, 131, 10.1097/CAD.0b013e328333d662 Makris, 2007, Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer, BMC Cancer, 7, 150, 10.1186/1471-2407-7-150 Tammaro, 2005, Interstitial lung disease following erlotinib (Tarceva®) in a patient who previously tolerated gefitinib (Iressa®), J Oncol Pharm Pract, 11, 127, 10.1191/1078155205jp158cr Hicks, 2004, Early FDG-PET imaging after radical radiotherapy for non–small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation, Int J Radiat Oncol Biol Phys, 60, 412, 10.1016/j.ijrobp.2004.03.036 Kong, 2007, A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer, J Clin Oncol, 25, 3116, 10.1200/JCO.2006.10.3747 Hart, 2008, Radiation pneumonitis: correlation of toxicity with pulmonary metabolic radiation response, Int J Radiat Oncol Biol Phys, 71, 967, 10.1016/j.ijrobp.2008.04.002 Guerrero, 2007, Radiation pneumonitis: local dose versus [18F]-fluorodeoxyglucose uptake response in irradiated lung, Int J Radiat Oncol Biol Phys, 68, 1030, 10.1016/j.ijrobp.2007.01.031 McCurdy, 2012, [18F]-FDG uptake dose–response correlates with radiation pneumonitis in lung cancer patients, Radiother Oncol, 104, 52, 10.1016/j.radonc.2012.04.003 Chen, 2006, FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin, J Appl Physiol, 100, 1602, 10.1152/japplphysiol.01429.2005 Gridley, 2004, Time course of serum cytokines in patients receiving proton or combined photon/proton beam radiation for resectable but medically inoperable non-small-cell lung cancer, Int J Radiat Oncol Biol Phys, 60, 759, 10.1016/j.ijrobp.2004.04.022 Siva, 2014, A pattern of early radiation-induced inflammatory cytokine expression is associated with lung toxicity in patients with non-small cell lung cancer, PLoS One, 9, 10.1371/journal.pone.0109560 Eilertsen, 1994, Methods for fully automated verification of patient set-up in external beam radiotherapy with polygon shaped fields, Phys Med Biol., 39, 993, 10.1088/0031-9155/39/6/006 Eide, 2016, Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease, Clin Transl Immunol, 5, 10.1038/cti.2016.65 Hill, 2008, Gene Ontology annotations: what they mean and where they come from, BMC Bioinformatics, 9, S2, 10.1186/1471-2105-9-S5-S2 Gene Ontology Consortium, 2001, Creating the gene ontology resource: design and implementation, Genome Res, 11, 1425, 10.1101/gr.180801 Basu, 2010, PET and PET-CT imaging in infection and inflammation: Its critical role in assessing complications related to therapeutic interventions in patients with cancer, Indian J Cancer, 47, 371, 10.4103/0019-509X.73562 Groves, 2009, Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT, J Nucl Med, 50, 538, 10.2967/jnumed.108.057901 Yamashita, 2015, Lymphangiogenic factors are associated with the severity of hypersensitivity pneumonitis, BMJ Open Respir Res, 2, 10.1136/bmjresp-2015-000085 Eberhard, 2004, Up-regulation of the chemokine CCL21 in the skin of subjects exposed to irritants, BMC Immunol, 26, 5 Serra, 2004, Secondary lymphoid tissue chemokine (CCL21) is upregulated in allergic contact dermatitis, Int Arch Allergy Immunol, 133, 64, 10.1159/000076129 Thatcher, 2009, Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.k, Oncologist, 14, 840, 10.1634/theoncologist.2009-0055 Topalian, 2016, Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy, Nat Rev Cancer, 16, 275, 10.1038/nrc.2016.36